Effectiveness of OjasNoor Renewal Serum for Brightening

A Clinical Study to Evaluate the Effectiveness of OjasNoor Renewal Serum for Brightening - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2026/07/114186

Enrollment

Registered

2026-07-16

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product: OjasNoor Renewal Serum: Dose: 0.5 to 1gm twice a day Route of Administration: Topical Duration: 28 days Control Intervention1: Not Applicabal: Not Applicabal

Eligibility

Inclusion criteria

Inclusion criteria: 1. Gender: Male and Female with age 18-45. 2. Subjects presenting with dull-looking skin and visible fine lines and wrinkles. 3. Subjects willing to give written informed consent 4. Women of child bearing potential must have a negative urine pregnancy test prior to study entry. 5. Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events. 6. Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation natural or artificial for the duration of the study.

Exclusion criteria

Exclusion criteria: 1. Have any evidence of systemic cancer, squamous cell carcinoma, basal cell carcinoma, in the last 5 years, or any other confounding skin condition. 2. Have open sores or open lesions in the treatment area. 3. Have any condition that, in the opinion of the investigator, would confound the safety and efficacy assessments of the product. 4. Have participated in any interventional clinical trial in the previous 90 days. 5. Have a known sensitivity to any of the constituents of the test product including sensitivities to mention some of active ingredient name 6. Have used, are using, or are planning to use immunosuppressive or immunomodulatory medication such as biologics, including corticosteroids. 7. Have not skin related issues.

Design outcomes

Primary

Measure	Time frame
1. Change in pigmentation 2. Change in skin color 3. Change in Hydration 4. Change in TEWL 5. Change in Firmness 6. Change in Elasticity 7. Change in Wrinkle depth and Length 8. Dermat Evaluation 9. Dermascopy Images 10. HD ImagingTimepoint: At Day0, Day14 and Day28	—

Secondary

Measure	Time frame
Subject Self Assessments.Timepoint: At Day 28	—

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org08937015757

Outcome results